Clinical Trial Update: A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating a DNAJB1-PRKACA fusion kinase peptide vaccine in combination with DRP-104, nivolumab, and ipilimumab for advanced fibrolamel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrolamellar Hepatocellular Carcinoma

Drugs mentioned

• DNAJB1-PRKACA Fusion Kinase Peptide Vaccine
• DRP-104
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | Phase 1 | Status: NOT_YET_RECRUITING